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• Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by fibrosis,
inflammation, autoantibody formation, and vascular abnormalities.
• There are approximately 100,000 SSc patients in the US. The incidence and prevalence rates
are much higher in females than in males.
• There are currently no validated diagnostic markers, disease altering FDA-approved
treatments or cures for this disease.
• Mechanism of disease pathogenesis is poorly understood.
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• Flow	cytometry	was	performed	using an 8-color MACSQuant 10 with three laser sources (405 nm, 488 nm, 635 nm) and 
FlowLogic 501.2A software.
CDDO-Me inhibits inflammatory and fibrotic mediator production in both healthy and SSc
macrophages, resulting in decreased collagen production and inflammation.
Figure 1: Model of SSc pathogenesis. Genetic and environmental factors converge to cause the
onset of SSc. There are four hallmarks of the disease that include vascular abnormalities,
fibrosis, oxidative stress, and aberrant immune function.
• Macrophages are innate immune cells that play important roles in phagocytosis, antigen
presentation, and cytokine and chemokine production.
• Macrophage activation is plastic and is influenced by the local tissue micro-environment,
including cytokines, chemokines, growth factors, and hormones.
• Genes associated with monocyte and macrophage recruitment and differentiation are
overexpressed in SSc patients.
• Expression of TGF-β, CCL2, and IL-6, which are known to induce fibrosis, inflammation and
oxidative stress, is elevated in SSc macrophages.
• CDDO-Me is an orally-bioavailable semi-synthetic triterpenoid with anti-inflammatory and
anti-carcinogenic properties.
• CDDO-Me is undergoing Phase III clinical trial testing for the treatment of pulmonary arterial
hypertension, which is the leading cause of death in SSc patients.
HYPOTHESIS
CDDO-Me	attenuates	CCL2	levels	in	both	healthy	and	systemic	sclerosis	macrophages CONCLUSIONS
Figure 3: Control and SSc macrophages were
treated with DMSO or 300nM CDDO-Me for 24
hours. Total RNA was extracted, reverse
transcribed into cDNA and target genes were
amplified using qRT-PCR. Values were







Figure 4: Control and SSc macrophages were
treated with DMSO or 300nM CDDO-Me for 24
hours. Total RNA was extracted and reverse
transcribed into cDNA. Message for target genes
was amplified using qRT-PCR and normalized
using b-actin. n=3 for each experiment.
CDDO-Me	decreases	%	CD206+	healthy	and	SSc	macrophages
Figure 5: Multicolor flow cytometry was used to analyze effect of CDDO-Me on surface
expression of CD163 and CD206. Healthy and SSc macrophages were treated with DMSO or









CDDO-Me attenuates expression of pro-fibrotic CCL2 and induces Nrf2 activation in
SSc macrophages, suggesting it may be useful as a therapeutic for SSc patients.
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